Revance Therapeutics Executive and Leadership Team

Nadeem Moiz, the Chief Executive Officer at Revance Therapeutics, directs the company's overall strategic vision and operational execution. Moiz guides the development and commercialization of novel botulinum toxin products, focusing on advancing DaxibotulinumtoxinA for injection (RT002) through clinical trials for aesthetic and therapeutic indications. Overseeing all corporate functions, the Chief Executive Officer ensures alignment with market opportunities and regulatory requirements. This leadership role involves fostering innovation and driving the company's growth trajectory in the competitive biotechnology landscape. By championing research and development initiatives, Nadeem Moiz secures the company's position in pioneering new treatments for glabellar lines, cervical dystonia, and plantar fasciitis, ultimately impacting patient quality of life and market penetration.

Scott Leffler, the Chief Financial Officer at Revance Therapeutics, manages the company's financial strategy and fiscal operations. Leffler oversees all aspects of financial planning, budgeting, and capital allocation, ensuring robust financial health to support ongoing research and development. Directing financial reporting and investor relations, the Chief Financial Officer provides critical insights into the company's economic performance and future outlook. This position involves securing funding for clinical trials and commercial expansion, managing risk, and optimizing resource utilization across all departments. By maintaining stringent financial controls and strategic fiscal management, Scott Leffler enables Revance Therapeutics to pursue its mission of developing and commercializing innovative botulinum toxin products, thereby supporting long-term shareholder value and operational sustainability.

Nicholas Crowe, the Chief Operating Officer at Revance Therapeutics, directs the company's day-to-day operational activities and ensures efficient execution of business strategies. Crowe oversees manufacturing, supply chain logistics, and quality control, guaranteeing the reliable production of DaxibotulinumtoxinA for injection and other product candidates. Driving operational excellence, the Chief Operating Officer optimizes processes to support clinical trial timelines and market readiness. This role involves managing cross-functional collaboration to streamline workflows and enhance productivity across the organization. By implementing effective operational frameworks, Nicholas Crowe ensures that Revance Therapeutics can scale its production capabilities and meet market demand for its innovative aesthetic and therapeutic solutions, contributing directly to the company's overall success and impact.

Satish Kalala, the Chief Technology Officer at Revance Therapeutics, architects the company's technological infrastructure and innovation pipeline. Kalala oversees the research and development efforts, particularly focusing on the manufacturing and formulation of novel botulinum toxin products like DaxibotulinumtoxinA for injection and its topical gel counterpart. Driving technological advancements, the Chief Technology Officer ensures the scientific integrity and scalability of production processes. This critical role involves managing the integration of cutting-edge biotechnology solutions to support clinical trials and eventual commercialization. By leading the technical teams, Satish Kalala ensures the company maintains a competitive edge through robust scientific discovery and efficient product development, directly supporting the advancement of treatments for aesthetic and therapeutic needs.

Steven Kreider, the Executive Vice President & Chief Revenue Officer, Aesthetics & Therapeutics at Revance Therapeutics, spearheads the commercialization and revenue generation strategies for the company's product portfolio. Kreider directs sales, marketing, and market access initiatives, focusing on expanding the reach of DaxibotulinumtoxinA for injection in both aesthetic and therapeutic markets. Driving revenue growth, the Chief Revenue Officer cultivates key partnerships and develops go-to-market plans to maximize market penetration and adoption. This leadership position involves translating scientific innovation into commercial success, ensuring that patients and healthcare providers benefit from Revance's advanced treatments. By leading the commercial teams, Steven Kreider secures significant market share and financial performance, directly contributing to the company's mission of transforming patient care.

Matthew Argano, the Chief Human Resources Officer at Revance Therapeutics, leads the company's talent management and organizational development strategies. Argano oversees all human resources functions, including recruitment, employee relations, compensation, and benefits, ensuring a high-performing and engaged workforce. Cultivating a strong corporate culture, the Chief Human Resources Officer fosters an environment that supports innovation and collaboration, critical for a biotechnology firm. This role involves developing and implementing HR policies that align with the company's strategic objectives and regulatory compliance. By attracting, retaining, and developing top talent, Matthew Argano ensures Revance Therapeutics has the skilled personnel necessary to advance its novel botulinum toxin products and achieve its business goals, underpinning the company's long-term success.

Kira Schwartz, the Chief Legal Officer at Revance Therapeutics, provides strategic legal counsel and oversees all legal affairs for the company. Schwartz manages corporate governance, intellectual property protection, regulatory compliance, and litigation, safeguarding the company's interests. Ensuring legal integrity, the Chief Legal Officer advises the executive team and the Board of Directors on critical legal matters related to product development, clinical trials, and commercialization. This position involves navigating complex regulatory landscapes and mitigating legal risks associated with the biotechnology industry. By providing expert legal guidance, Kira Schwartz supports the company's mission to develop and commercialize innovative botulinum toxin products, ensuring adherence to all applicable laws and ethical standards, and protecting the company's valuable assets and reputation.